Abstract
Introduction: Guillain-Barre syndrome (GBS) is an acute autoimmune disorder of peripheral nerves and their roots. The most common GBS variants are: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS) and other rarer variants. Aim: Evaluation of frequency of GBS variants and analysis of the outcome of the disease in a cohort of patients hospitalized at the Neurology Clinic, Clinical Center of Serbia. Material and Methods: This study included 43 patients with GBS, hospitalized in 2015. The data about clinical characteristics of the disease were collected by a retrospective analysis from electronic medical record. We used methods of descriptive statistics: mean, standard deviation and proportions. Results: Majority of our patients were male with male to female ratio 2.6 : 1. The most common variant in our study was AIDP (41.9%), then AMSAN (7.0%) and AMAN (4.7%). The most common first symptoms of the disease were weakness and numbness in the legs (18.6%). According to the Hughes scale, at admission, most of the patients had a mild form of the disease (65.1%), while at nadir 62.8% were non ambulatory, and 2.3% of patients required assisted ventilation. The outcome of the disease was favorable in 74.4% of patients, while 11 patients (25.6%) had a significant functional disability on discharge. In (4.7%) 2 patients of our cohort, lethal outcome was recorded. Conclusion: GBS is a rapidly progressive, monophasic disease, which has a generally good prognosis today, thanks to modern therapy. Our further research will be focused on the long-term outcome of GBS.
Highlights
Guillain-Barré syndrome (GBS) is an acute autoimmune disorder of peripheral nerves and their roots
Evaluation of frequency of GBS variants and analysis of the outcome of the disease in a cohort of patients hospitalized at the Neurology Clinic
The data about clinical characteristics of the disease were collected by a retrospective analysis from electronic medical record
Summary
Guillain-Barré syndrome (GBS) is an acute autoimmune disorder of peripheral nerves and their roots. Uvod: Gijen-Bareov (Guillain-Barré) sindrom (GBS) akutno je autoimuno oboljenje perifernih nerava i njihovih korijenova. Najčešće varijante oboljenja su: akutna inflamatorna demijelinizaciona polineuropatija (AIDP), akutna motorna aksonalna neuropatija (AMAN), akutna motorna i senzorna aksonalna neuropatija (AMSAN), Miler-Fišerov (Miller-Fisher) sindrom (MFS) i druge rijeđe forme. Patohistološkim i kliničkim karakteristikama, razlikuje se nekoliko varijanti GBS: akutna inflamatorna demijelinizaciona polineuropatija (AIDP), akutna motorna aksonalna neuropatija (AMAN), akutna motorna i senzorna aksonalna neuropatija (AMSAN), faringocervikobrahijalna varijanta (PCB), Miler-Fišerov (Miller-Fisher) sindrom (MFS), kao i neki drugi, rijeđi, subtipovi (7). Ciljevi ovog istraživanja bile su analiza kliničkih karakteristika i procijena kratkoročnog ishoda GBS u kohorti bolesnika hospitalizovanih na Odjeljenju za neuromišićne bolesti i na Odjeljenju urgentne neurologije Klinike za neurologiju Kliničkog centra Srbije u jednogodišnjem periodu od 1.1.2015. Ciljevi ovog istraživanja bile su analiza kliničkih karakteristika i procijena kratkoročnog ishoda GBS u kohorti bolesnika hospitalizovanih na Odjeljenju za neuromišićne bolesti i na Odjeljenju urgentne neurologije Klinike za neurologiju Kliničkog centra Srbije u jednogodišnjem periodu od 1.1.2015. do 1.1.2016. godine
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.